-
Press Release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Press Release
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
-
Story
A legacy of blood cancer innovation -
Press Release
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
-
Story
Compassionate use: Providing access to much needed treatments -
Story
Renewing our commitment to neglected tropical disease and malaria elimination -
Story
When it comes to cancer, there’s power in a good partner -
Press Release
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
-
Press Release
Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
-
Story
Toward improving the health and longevity of transplanted organs -
Story
Researchers boost understanding of T-cell therapy in blood cancer -
Story
Going the extra mile to keep clinical trials on track during the COVID-19 pandemic